NewBiologix, a Swiss technology company specializing in viral vector production for cell and gene therapies, has announced the opening of its new U.S. subsidiary.
The launch of the company’s U.S. hub, which will provide real-time support and collaboration for cell and gene therapy (CGT) companies, coincides with the introduction of its Xcell portfolio, a suite of technologies designed to streamline recombinant adeno-associated virus (rAAV) production.
